Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Kristi A, Boehm"'
Autor:
Thomas L. Hunt, LuAnn Bundrant, Alan Wilson, Kenneth Kassler-Taub, Chris Warner, Phil Banks, Praveen Tyle, Suma Gopinathan, Suman Wason, Kristi A. Boehm
Publikováno v:
Clinical therapeutics. 43(6)
Purpose For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase I studies of LX9211, a new small-molecule AP2-associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a718db9c0cb48300a58b7740a2bfe9e
https://pubmed.ncbi.nlm.nih.gov/34108079
https://pubmed.ncbi.nlm.nih.gov/34108079
Autor:
Efsevia Vakiani, George Birchfield, Shaker R. Dakhil, Leonard B. Saltz, David B. Solit, Laurence K. Tokaz, Feng Zhan, Bryan Bienvenu, Marinella Capanu, David Barrera, Mark Allen O'Rourke, Allen Lee Cohn, Donald A. Richards, Paul Conkling, Suprith Badarinath, Amy Scales, W. Graydon Harker, Lina Asmar, Kristi A. Boehm, Diane Lauren Reidy
Publikováno v:
Clinical Colorectal Cancer. 11:101-111
Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and bevacizumab (B), and preliminary data of cetuximab + bevacizumab, and toxicity pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::674dad36dde9a6580599e7be6e385492
https://doi.org/10.1016/j.clcc.2011.05.006
https://doi.org/10.1016/j.clcc.2011.05.006
Autor:
Lawrence E. Garbo, Lianchun Xiao, Brittany North, Ralph E. Weinstein, Ana Aparicio, Mark D. Fleming, William R. Berry, Guru Sonpavde, Feng Zhan, Lina Asmar, Kristi A. Boehm, Matthew D. Galsky, Steven R. Rousey, Robert Delaune, Daniel D. Von Hoff
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 29:682-689
Azacitidine is a hypomethylating agent that activates genes repressed by promoter methylation. Preclinically, demethylating agents reverse resistance of prostate cancer to androgen ablation. A phase II trial evaluated azacitidine for men with castrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::046f6bedb2b7edeac68e026bc49aff09
https://doi.org/10.1016/j.urolonc.2009.09.015
https://doi.org/10.1016/j.urolonc.2009.09.015
Autor:
Lina Asmar, Romeo A. Mandanas, Roy A. Beveridge, Joe Stephenson, George T. Kannarkat, John F. Schwerkoske, Feng Zhan, Kristi A. Boehm, Andrew Greenspan, Robert M. Rifkin
Publikováno v:
Investigational New Drugs. 30:714-722
Background A majority of multiple myeloma (MM) patients fail to achieve complete response (CR) to peripheral blood stem cell transplantation (PBSCT); effective options following autologous transplantation are needed. Bortezomib (B) is active against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::096c110287f8b33432962770e7180d99
https://doi.org/10.1007/s10637-010-9556-6
https://doi.org/10.1007/s10637-010-9556-6
Autor:
John D. Hainsworth, John Pippen, Neil Senzer, Lina Asmar, John Sandbach, F. Anthony Greco, Svetislava J. Vukelja, Scot Sedlacek, David M. Loesch, Kristi J. McIntyre, Manuel Modiano, Kristi A. Boehm, Feng Zhan, Howard A. Burris, Deborah Lindquist, Frankie A. Holmes, Nicholas J. Robert, Stephen E. Jones, Joanne L. Blum
Publikováno v:
Journal of Clinical Oncology. 28:2958-2965
Purpose This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer. Methods Women (who had performance status [PS] of 0 to 1) with operable, histologically confirmed, stage I to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918360d9aea45dbdf9736d163d90f0ca
https://doi.org/10.1200/jco.2009.24.1000
https://doi.org/10.1200/jco.2009.24.1000
Autor:
Lina Asmar, Dean S. McGaughey, Kristi A. Boehm, Feng Zhan, Robert M. Rifkin, Gary Spitzer, Roy A. Beveridge, Romeo A. Mandanas, Gregory Orloff
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 10:186-191
Background Filgrastim decreases the time to neutrophil recovery after autologous peripheral blood stem cell transplantation (PBSCT). We hypothesized that single-dose pegfilgrastim would mimic multiple daily doses of filgrastim, resulting in an equiva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4375e4c0d00068466b167b5a2fe049
https://doi.org/10.3816/clml.2010.n.029
https://doi.org/10.3816/clml.2010.n.029
Autor:
Guru Sonpavde, F. Zhan, D. M. Bernold, Thomas E. Hutson, Lina Asmar, P. O. Periman, Kristi A. Boehm, D. J. Weckstein, M.T. Fleming, William R. Berry, Matthew D. Galsky
Publikováno v:
Annals of Oncology. 21:319-324
Background Systemic therapy options are limited for metastatic castration-resistant prostate cancer (CRPC) patients who progress following docetaxel (Taxotere). This phase II trial evaluated sunitinib malate in patients with progressing metastatic CR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a6c332a3430d0550d3c4858f13de987
https://doi.org/10.1093/annonc/mdp323
https://doi.org/10.1093/annonc/mdp323
Autor:
Roger M. Lyons, Yunfei Wang, Philip Y. Dien, Nicholas J. Di Bella, Robert N. Raju, Julie Boston, Kathryn S. Kolibaba, Svetislava J. Vukelja, David Barrera, Raymond Taetle, Peter J. Schlegel, Thomas E. Boyd, Lina Asmar, Kristi A. Boehm, Ernest W. Cochran
Publikováno v:
Blood. 115:475-480
This study evaluated the efficacy and safety of single-agent bortezomib in indolent B-cell lymphoma that had relapsed from or was refractory to rituximab. Sixty patients enrolled: 59 were treated with bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d55ec35c8ddf369b27ca9c691a5c244
https://doi.org/10.1182/blood-2009-08-233155
https://doi.org/10.1182/blood-2009-08-233155
Autor:
Craig W. Reynolds, David Barrera, Sharon Pritchard, Alexander I. Spira, Charles Weissman, Lina Asmar, Robert M. Jotte, Kristi A. Boehm
Publikováno v:
Journal of Thoracic Oncology. 4:1537-1543
IntroductionCarboplatin/paclitaxel chemotherapy with bevacizumab is an accepted standard treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). The development of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has circumvented
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e098c89160c23bbce94204f183897f
https://doi.org/10.1097/jto.0b013e3181c0a2f4
https://doi.org/10.1097/jto.0b013e3181c0a2f4
Autor:
Xueli Li, Jane Bromund, David Boulware, Lina Asmar, Mark A. O'Rourke, Gail S. Wright, Michael J. Schell, Zhong Zheng, Kristi A. Boehm, Coleman K. Obasaju, Matthew J. Monberg, Linda Cheryl DeMarco, Gerold Bepler, John R. Caton, Guangbin Peng, Craig W. Reynolds
Publikováno v:
Journal of Clinical Oncology. 27:5808-5815
Purpose We evaluated the efficacy of gemcitabine versus gemcitabine and carboplatin in patients with advanced non–small-cell lung cancer (NSCLC) and a performance status (PS) of 2 and assessed if tumoral RRM1 and ERCC1 protein levels are predictive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d47e65755a60a9458df5862d9f973d71
https://doi.org/10.1200/jco.2009.21.9766
https://doi.org/10.1200/jco.2009.21.9766